CrystalGenomics, Inc. (083790.KQ)
KRW 2545.0
(0.99%)
KRW 2545.0
(0.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 97.82 Billion USD | -24.28% |
| 2022 | 129.19 Billion USD | 9.2% |
| 2021 | 118.3 Billion USD | 22.53% |
| 2020 | 96.54 Billion USD | 731.58% |
| 2019 | 11.6 Billion USD | 6.83% |
| 2018 | 10.86 Billion USD | 1.68% |
| 2017 | 10.68 Billion USD | 2.9% |
| 2016 | 10.38 Billion USD | 5.95% |
| 2015 | 9.8 Billion USD | 7.51% |
| 2014 | 9.11 Billion USD | 6.29% |
| 2013 | 8.57 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 99.04 Billion KRW | 1.25% |
| 2024 Q2 | 109.78 Billion KRW | 10.84% |
| 2023 FY | 97.82 Billion USD | -24.28% |
| 2023 Q1 | 149.34 Billion USD | 656.99% |
| 2023 Q3 | 158.6 Billion USD | -27.06% |
| 2023 Q2 | 217.44 Billion KRW | 45.6% |
| 2023 Q4 | 97.82 Billion USD | -38.32% |
| 2022 FY | 129.19 Billion USD | 9.2% |
| 2022 Q3 | 18.81 Billion USD | 0.0% |
| 2022 Q1 | 17.9 Billion USD | 4.02% |
| 2022 Q4 | 19.72 Billion USD | 4.87% |
| 2021 Q4 | 17.21 Billion USD | 5.53% |
| 2021 FY | 118.3 Billion USD | 22.53% |
| 2021 Q1 | 15.9 Billion USD | 1.96% |
| 2021 Q3 | 16.31 Billion USD | 0.0% |
| 2020 Q1 | 14.53 Billion USD | 0.4% |
| 2020 Q4 | 15.59 Billion USD | 1.92% |
| 2020 FY | 96.54 Billion USD | 731.58% |
| 2020 Q3 | 15.3 Billion USD | 0.0% |
| 2019 FY | 11.6 Billion USD | 6.83% |
| 2019 Q4 | 14.47 Billion USD | 24.69% |
| 2019 Q1 | 11.36 Billion USD | 0.21% |
| 2019 Q3 | 11.6 Billion USD | 0.0% |
| 2018 Q1 | 10.66 Billion USD | -0.66% |
| 2018 FY | 10.86 Billion USD | 1.68% |
| 2018 Q4 | 11.33 Billion USD | 4.34% |
| 2018 Q3 | 10.86 Billion USD | 0.0% |
| 2017 Q1 | 10.74 Billion USD | 0.12% |
| 2017 Q4 | 10.73 Billion USD | 0.43% |
| 2017 Q3 | 10.68 Billion USD | 0.0% |
| 2017 FY | 10.68 Billion USD | 2.9% |
| 2016 Q1 | 10.32 Billion USD | 2.17% |
| 2016 Q3 | 10.38 Billion USD | 0.0% |
| 2016 Q4 | 10.73 Billion USD | 3.3% |
| 2016 FY | 10.38 Billion USD | 5.95% |
| 2015 Q1 | 9.67 Billion USD | 3.15% |
| 2015 FY | 9.8 Billion USD | 7.51% |
| 2015 Q4 | 10.1 Billion USD | 3.1% |
| 2015 Q3 | 9.8 Billion USD | 0.0% |
| 2014 Q1 | 9.18 Billion USD | 4.98% |
| 2014 FY | 9.11 Billion USD | 6.29% |
| 2014 Q4 | 9.37 Billion USD | 2.86% |
| 2014 Q3 | 9.11 Billion USD | 0.0% |
| 2013 Q4 | 8.74 Billion USD | 1.93% |
| 2013 Q3 | 8.57 Billion USD | 0.0% |
| 2013 FY | 8.57 Billion USD | 0.0% |
| 2013 Q1 | 8.31 Billion USD | 1.26% |
| 2012 Q4 | 8.21 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Co., Ltd. | 169.47 Billion KRW | 42.279% |
| iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -5102.325% |
| BINEX Co., Ltd. | 75.68 Billion KRW | -29.248% |
| Bioneer Corporation | 80.61 Billion KRW | -21.352% |
| Anterogen.Co.,Ltd. | 19.98 Billion KRW | -389.437% |
| MEDIPOST Co., Ltd. | 135.73 Billion KRW | 27.931% |
| Helixmith Co., Ltd | 73.55 Billion KRW | -32.988% |
| Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 90.851% |
| Medy-Tox Inc. | 137.14 Billion KRW | 28.67% |
| Peptron, Inc. | 16.36 Billion KRW | -497.61% |
| Amicogen, Inc. | 248.12 Billion KRW | 60.575% |
| Genexine, Inc. | 79.68 Billion KRW | -22.765% |
| HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -234.139% |
| LegoChem Biosciences, Inc. | 41.28 Billion KRW | -136.968% |
| ALTEOGEN Inc. | 108.25 Billion KRW | 9.64% |
| PharmaResearch Co., Ltd. | 73.08 Billion KRW | -33.845% |
| SillaJen, Inc. | 19.4 Billion KRW | -404.216% |
| JETEMA, Co., Ltd. | 179.09 Billion KRW | 45.378% |
| OliX Pharmaceuticals,Inc | 52.48 Billion KRW | -86.367% |
| Genomictree Inc. | 7.81 Billion KRW | -1152.166% |
| MedPacto, Inc. | 9.56 Billion KRW | -922.636% |
| D&D Pharmatech | 23.98 Billion KRW | -307.838% |
| EASY BIO,Inc. | 105.86 Billion KRW | 7.6% |
| GI Innovation, Inc. | 9.63 Billion KRW | -915.157% |